Close Menu

Lucigen

LGC provides customers across multiple markets with reference materials, proficiency testing, oligonucleotides, genomics reagents, and instrumentation.

LGC Acquires Lucigen

London-based LGC said that the acquisition increases its exposure to the next-generation sequencing and gene editing markets.

The Madison, Wisconsin-based company is expanding its global operations with distribution deals in Turkey, South Africa, Russia, and Australia.

Lucigen has signed a global agreement with Illumina to be the sole distributor of Epicentre Technologies' genomics kits, enzymes, and ancillary reagents.

The exclusive agreement covers a portfolio of Epicentre products for transposomics, microarray analysis, and transcriptomics research.

The CSPro certification program is a two-step process that includes minimum data generation, data certification, and an on-site audit of a facility and its processes.

The firm presented results of a pre-clinical evaluation of the test and platform yesterday at the Next Generation Dx Summit in Washington, DC. 

Lucigen's CEO said the agreement will provide researchers in India with his firm's technologies for use with NGS, cloning, and protein expression systems.

The proceeds will be used to fund development of a molecular diagnostics platform and for clinical trials to gain FDA approval for the platform.

NEW YORK (GenomeWeb) – Using fever to screen for Ebola casts a wide net, while standard RT-PCR requires many hours and expert technicians.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.